Cargando…

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status

An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yan-Rong, Cao, Qing-Dong, Hong, Zhong-Si, Tan, Yuan-Yang, Chen, Shou-Deng, Jin, Hong-Jun, Tan, Kai-Sen, Wang, De-Yun, Yan, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068984/
https://www.ncbi.nlm.nih.gov/pubmed/32169119
http://dx.doi.org/10.1186/s40779-020-00240-0
_version_ 1783505686291808256
author Guo, Yan-Rong
Cao, Qing-Dong
Hong, Zhong-Si
Tan, Yuan-Yang
Chen, Shou-Deng
Jin, Hong-Jun
Tan, Kai-Sen
Wang, De-Yun
Yan, Yan
author_facet Guo, Yan-Rong
Cao, Qing-Dong
Hong, Zhong-Si
Tan, Yuan-Yang
Chen, Shou-Deng
Jin, Hong-Jun
Tan, Kai-Sen
Wang, De-Yun
Yan, Yan
author_sort Guo, Yan-Rong
collection PubMed
description An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.
format Online
Article
Text
id pubmed-7068984
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70689842020-03-18 The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status Guo, Yan-Rong Cao, Qing-Dong Hong, Zhong-Si Tan, Yuan-Yang Chen, Shou-Deng Jin, Hong-Jun Tan, Kai-Sen Wang, De-Yun Yan, Yan Mil Med Res Review An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus. BioMed Central 2020-03-13 /pmc/articles/PMC7068984/ /pubmed/32169119 http://dx.doi.org/10.1186/s40779-020-00240-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Guo, Yan-Rong
Cao, Qing-Dong
Hong, Zhong-Si
Tan, Yuan-Yang
Chen, Shou-Deng
Jin, Hong-Jun
Tan, Kai-Sen
Wang, De-Yun
Yan, Yan
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
title The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
title_full The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
title_fullStr The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
title_full_unstemmed The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
title_short The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
title_sort origin, transmission and clinical therapies on coronavirus disease 2019 (covid-19) outbreak – an update on the status
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068984/
https://www.ncbi.nlm.nih.gov/pubmed/32169119
http://dx.doi.org/10.1186/s40779-020-00240-0
work_keys_str_mv AT guoyanrong theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT caoqingdong theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT hongzhongsi theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT tanyuanyang theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT chenshoudeng theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT jinhongjun theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT tankaisen theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT wangdeyun theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT yanyan theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT guoyanrong origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT caoqingdong origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT hongzhongsi origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT tanyuanyang origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT chenshoudeng origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT jinhongjun origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT tankaisen origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT wangdeyun origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus
AT yanyan origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus